Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Bicycle Therapeutics PLC as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- 0 vs. Q3 2023
- Shares held
- 31.4M
- −1.03M (−3.2%) vs. Q3 2023
- Total value
- $567.4M
- −$83.9M (−12.9%) vs. Q3 2023
- New holders
- 21
- 35 more added
- Sold out
- 21
- 32 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Arete Wealth Advisors, LLC | 3,772 | – | – | +3,772 | New |
| Braidwell LP | 0 | $0 | 0.00% | −1,289,872−100.0% | Sold out |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −910,930−100.0% | Sold out |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −796,933−100.0% | Sold out |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −448,753−100.0% | Sold out |
| AlphaCentric Advisors LLC | 0 | $0 | 0.00% | −58,500−100.0% | Sold out |
| Ghisallo Capital Management LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −31,534−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −27,957−100.0% | Sold out |
| AE Wealth Management LLC | 0 | $0 | 0.00% | −24,773−100.0% | Sold out |
| Mach-1 Financial Group, Inc. | 0 | $0 | 0.00% | −24,701−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −22,500−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −16,076−100.0% | Sold out |
| Sandia Investment Management LP | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| BIT Capital GmbH | 0 | $0 | 0.00% | −4,850−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −2,400−100.0% | Sold out |
| BluePath Capital Management, LLC | 0 | $0 | 0.00% | −1,534−100.0% | Sold out |
| Raleigh Capital Management Inc. | 0 | $0 | 0.00% | −185−100.0% | Sold out |
| Highline Wealth Partners LLC | 0 | $0 | 0.00% | −110−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −40−100.0% | Sold out |
| Bell Investment Advisors, Inc | 0 | $0 | 0.00% | −24−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −12−100.0% | Sold out |